FBXL6 is overexpressed in various cancers and is correlated with the unfavorable prognosis of the disease, such as gastric cancer, colorectal cancer, hepatocellular carcinoma, and renal cell carcinoma, etc. (Shi et al., 2020; Meng et al., 2023; Yu et al., 2022). Here, FBXL6 is linked to renal cell carcinoma.